These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37301439)

  • 1. Plasma and intraperitoneal pharmacokinetics of ceftazidime/avibactam in peritoneal dialysis patients.
    Al Jalali V; Matzneller P; Pham AD; van Os W; Wölfl-Duchek M; Sanz-Codina M; Vychytil A; Reiter B; Stimpfl T; Zeitlinger M
    Clin Microbiol Infect; 2023 Sep; 29(9):1196.e1-1196.e7. PubMed ID: 37301439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
    Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
    Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusion, therapeutic drug monitoring and outpatient parenteral antimicrobial therapy with ceftazidime/avibactam: a retrospective cohort study.
    Goncette V; Layios N; Descy J; Frippiat F
    J Glob Antimicrob Resist; 2021 Sep; 26():15-19. PubMed ID: 33989847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of ceftazidime/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa.
    Xu C; Zeng F; Huang Y; Xu Q; Yang Y; Gong W; Shi C; Zhang Y
    Int J Antimicrob Agents; 2024 Jan; 63(1):107021. PubMed ID: 37890733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A descriptive pharmacokinetic/pharmacodynamic analysis of ceftazidime-avibactam in a case series of critically ill patients with augmented renal clearance.
    Xu Y; Tang J; Yuan B; Luo X; Liang P; Liu N; Dong D; Jin L; Ge W; Gu Q
    Pharmacol Res Perspect; 2024 Feb; 12(1):e01163. PubMed ID: 38149723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia.
    Falcone M; Viale P; Tiseo G; Pai M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):331-340. PubMed ID: 29373935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of meropenem in patients undergoing automated peritoneal dialysis.
    Ullah S; Ursli M; Fuhr U; Wiesholzer M; Kussmann M; Poeppl W; Zeitlinger M; Taubert M
    Perit Dial Int; 2023 Sep; 43(5):402-410. PubMed ID: 37131320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
    Zhen S; Wang H; Feng S
    Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
    Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S
    BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
    Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
    mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.
    Zhuang HH; Chen Y; Hu Q; Long WM; Wu XL; Wang Q; Xu TT; Qu Q; Liu YP; Xiao YW; Qu J
    J Infect Public Health; 2023 Jun; 16(6):938-947. PubMed ID: 37087853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
    Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
    Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018.
    Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
    J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
    Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa.
    Corbella L; Boán J; San-Juan R; Fernández-Ruiz M; Carretero O; Lora D; Hernández-Jiménez P; Ruiz-Ruigómez M; Rodríguez-Goncer I; Silva JT; López-Medrano F; Lizasoain M; Villa J; Caro-Teller JM; Aguado JM
    Int J Antimicrob Agents; 2022 Feb; 59(2):106517. PubMed ID: 34990760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant
    Lopez-Montesinos I; Montero MM; Domene-Ochoa S; López-Causapé C; Echeverria D; Sorlí L; Campillo N; Luque S; Padilla E; Prim N; Grau S; Oliver A; Horcajada JP
    Antibiotics (Basel); 2022 Oct; 11(11):. PubMed ID: 36358110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.
    Tumbarello M; Raffaelli F; Giannella M; Mantengoli E; Mularoni A; Venditti M; De Rosa FG; Sarmati L; Bassetti M; Brindicci G; Rossi M; Luzzati R; Grossi PA; Corona A; Capone A; Falcone M; Mussini C; Trecarichi EM; Cascio A; Guffanti E; Russo A; De Pascale G; Tascini C; Gentile I; Losito AR; Bussini L; Corti G; Ceccarelli G; Corcione S; Compagno M; Giacobbe DR; Saracino A; Fantoni M; Antinori S; Peghin M; Bonfanti P; Oliva A; De Gasperi A; Tiseo G; Rovelli C; Meschiari M; Shbaklo N; Spanu T; Cauda R; Viale P
    Clin Infect Dis; 2021 Nov; 73(9):1664-1676. PubMed ID: 33618353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
    Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
    Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.